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Introduction: Ovarian cancer is considered a highly aggressive tumour, killing 
still 80% of patients. So far immunotherapy trials have yielded poor results, due 
to severe immunosuppression. Myeloid derived suppressor cells (MDSC) are a 
heterogeneous group of immature myeloid cells that have a strong 
immunosuppressive function. MDSC can be subdivided into monocytic MDSC 
(mMDSC) and granulocytic MDSC (gMDSC) based on the relative surface 
expression of lymphocyte antigen 6 complex locus C (Ly6C) and Ly6G in mice 
and cluster of differentiation 14 (CD14) and CD15 in humans. 
 
Material and method: The murine experiments were performed in C57BL/6 
mice (n=30) and Rag1tm1Mom mice (n=12), inoculated intraperitoneal (ip) with 5 x 
106 ID8-fLuc cells. Mice received ip injections with phosphate buffered saline 
(PBS), PBS liposomes or clodronate liposomes twice weekly starting from 
tumorinoculation. Six mice per group were evaluated for survival analysis. Three 
and four weeks after tumor challenge three mice per group were sacrificed for 
immune-monitoring on ascites and serum. Immune cells were characterized by 
fluorescent activated cell sorting (FACS), cytokines were determined by 
cytometric bead array (CBA). Next, peripheral blood mononuclear cells were 
collected prospectively in 39 patients at diagnosis of invasive ovarian cancer. 
MDSC were defined by FACS as live CD11b+HLA-DR- cells. 
 
Results and discussion: Mice treated with clodronate liposomes died 
significantly faster compared to immunocompetent mice (p=0.004), whereas the 
survival was not altered in mice lacking T- and B-cells (Rag1tm1Mom). After 
treatment with clodronate liposomes we observed a significant decrease in 
macrophages (p=0.001). mMDSC (live CD11B+Ly6CHi) increased significantly 
(p=0.004) after treatment with clodronate liposomes. In patient samples, we 
observed a significant decrease in progression free survival in patients with a 
high number of CD14+ mMDSC (p=0.03).  
 
Conclusion: The administration of clodronate liposomes significantly reduced 
survival of mice with ovarian cancer, most likely due to a depletion of 
macrophages and a significant increase in mMDSC. This is in accordance the 
situation in ovarian cancer patients, where increasing mMDSC are correlated 
with decreasing progression free survival.   
